Results 271 to 280 of about 43,955 (304)
Some of the next articles are maybe not open access.
Apolipoprotein(a) and atherogenesis
Pathology, 1992Lipoprotein(a) (Lp(a)) consists of a unique apolipoprotein, apolipoprotein(a), (apo(a)) linked by a disulphide bridge to apolipoprotein B of low density lipoprotein (LDL). Apo(a) is homologous with plasminogen and exhibits genetic polymorphism with the commoner phenotypes due to larger forms being associated with lower plasma levels and the less common
openaire +2 more sources
Apolipoprotein A-I mimetic peptides
Current Opinion in Lipidology, 2010To review published data related to the potential applicability of apolipoprotein A-I mimetic peptides.Despite a wealth of information on HDL-C levels and risk for cardiovascular disease (CVD), little evidence is present to suggest that raising HDL-C levels per se will result in CVD risk reduction.
G K, Hovingh +2 more
openaire +2 more sources
Free apolipoprotein (a) in abetalipoproteinaemia
Journal of Internal Medicine, 1989We have estimated the concentrations of free and lipoprotein-bound apo (a) antigen in plasma of a patient with abetalipoproteinaemia. The (a) antigen was quantified by electro-immunoassay using undiluted serum and by a two-site immunoradiometric assay with two different monoclonal antibodies in excess according to the same principles as described for ...
L, Holmquist, A, Hamsten, G H, Dahlén
openaire +2 more sources
Apolipoprotein(a): A Puzzling Evolutionary Story
Journal of Molecular Evolution, 1997Human apolipoprotein(a), a risk factor for heart disease, has over 80% sequence identity to plasminogen. Plasminogen contains five distinct kringle domains plus a catalytic protease subunit. Human apo(a) consists of multiple copies (the number varies in individuals) of a domain resembling kringle 4, a single copy of a domain resembling kringle 5, and a
Lawn R +3 more
openaire +3 more sources
Nihon rinsho. Japanese journal of clinical medicine, 1995
Apo (a) consists of multiple tandem repeat of kringle 4, which resembles a counterpart of plasminogen. Plasma Lp (a) levels are genetically determined primarily by alleles at the apo (a) gene. Apo (a) shows size heterogeneity on the analysis of the protein and the mRNA.
openaire +1 more source
Apo (a) consists of multiple tandem repeat of kringle 4, which resembles a counterpart of plasminogen. Plasma Lp (a) levels are genetically determined primarily by alleles at the apo (a) gene. Apo (a) shows size heterogeneity on the analysis of the protein and the mRNA.
openaire +1 more source
Nihon rinsho. Japanese journal of clinical medicine, 1995
Apolipoproteins A include apoA-I, apoA-II and apoA-IV. These apolipoproteins are involved in the metabolism of HDL and reverse cholesterol transport. The genes encoding apoA-I, apoA-II and apoA-IV have arisen from a common ancestor. This review describes the structures of the genes encoding apoA-I, apoA-II and apoA-IV, and the structures and functions ...
openaire +1 more source
Apolipoproteins A include apoA-I, apoA-II and apoA-IV. These apolipoproteins are involved in the metabolism of HDL and reverse cholesterol transport. The genes encoding apoA-I, apoA-II and apoA-IV have arisen from a common ancestor. This review describes the structures of the genes encoding apoA-I, apoA-II and apoA-IV, and the structures and functions ...
openaire +1 more source
Apolipoprotein A-IMilano: current perspectives
Current Opinion in Lipidology, 2003Strategies to increase HDL are among the major targets of clinical research in atherosclerosis prevention. The mutant apolipoprotein A-I(Milano) has been associated with a reduced incidence of coronary disease in carriers. Furthermore, recombinant apolipoprotein A-I(Milano) has displayed remarkable atheroprotective activities and the possibility of ...
G. Chiesa, C.R. Sirtori
openaire +2 more sources
Apolipoprotein B, apolipoprotein A-I, insulin resistance and the metabolic syndrome
Current Opinion in Lipidology, 2007The goal of identifying subjects with metabolic syndrome is to detect those at higher risk of developing cardiovascular disease. Evidence continues to accumulate as to the superiority of apolipoprotein B and apolipoprotein A-I over the conventional lipoprotein lipids as markers of vascular risk.
Allan D, Sniderman, May, Faraj
openaire +2 more sources
Mutants of Apolipoproteins A and C
1986The determination of the circulating levels of apolipoproteins has become common practice in clinical laboratories, in view of the apparent correlation between levels of specific apolipoproteins and increased or decreased cardiovascular risk [1, 2].
C. R. Sirtori, M. R. Lovati
openaire +3 more sources
Pharmacology of apolipoprotein A-l
Current Opinion in Lipidology, 1997The role of HDL and its main protein component the apolipoprotein A-I as being antiatherogenic is well established. Experimental data give support for the involvement of at least three different types of mechanism: (1) the reverse cholesterol transport, (2) anti-inflammatory mechanisms and (3) antithrombotic mechanisms.
openaire +2 more sources